207 results about "Regulatory T cell" patented technology

The invention discloses a cord blood-derived regulatory T cell amplification culture medium and a use method thereof, and relates to the field of animal cell culture and immune cell therapy, the culture medium is a serum-free culture medium, the culture medium is composed of a basic culture medium, a serum substitute combination, a combination of four cell factors, an immunosuppressor, an apparent stabilizer and an antioxidant, and all the components play a role synergistically; according to the use method, cell amplification is realized through a collaborative process of staged environmental regulation and targeted activation. According to the method, the problems of exogenous pollution and batch difference caused by dependence of a serum-containing system on cord blood-derived regulatory T cell amplification in the prior art are solved, the defect that a serum-free scheme is difficult to consider the amplification efficiency and the function stability at the same time is overcome, the cell amplification quality and the clinical application safety are guaranteed, and the method is suitable for large-scale clinical transformation requirements.

The invention relates to the technical field of biology, in particular to a Treg cell amplification culture medium and a preparation method of Treg cells. According to the method for in-vitro amplification of the regulatory T cells (Treg) from peripheral blood, the amplification efficiency and purity of the Treg cells are improved, the culture cost is reduced, the culture period is shortened, and the problem of trophoblast cell residues in subsequent clinical application is solved.

Therapeutic use and dosing regimen of anti-ICOS antibodies or antigen-binding fragments thereof for modulating the ratio between regulatory T cells and effector T cells, stimulating the immune system of patients, and / or treating tumours or cancers, as monotherapy or combination therapy, e.g., with anti-PD-L1 antibodies or antigen-binding fragments thereof.

The present invention relates to methods for carefully monitoring and evaluating the efficacy of cell therapy in patients treated with CD4+FoxP3+ regulatory T cells. Further subject matter relates to cell therapy methods using CD4+FoxP3+ regulatory T cells and the monitoring methods of the invention.

The present disclosure describes methods of specifically modulating the activity and / or number of regulatory T (Treg) cells within a tumor in a subject. Such methods may be used to reduce the number of regulatory T cells within a tumor in a subject, as well as to inhibit tumor growth in a subject with cancer without eliciting an autoimmune response. This method relies on the inhibition of CD36 or PPARbeta.

The application of phlorizin in the medicine for treating and / or preventing lupus nephritis, the molecular formula of phlorizin is C 21 H 24 O 10 , the application promotes the differentiation of regulatory T cells (Treg) by applying phlorizin to up-regulate the PI3K / Akt signal pathway, thereby reducing the symptoms of lupus nephritis, and provides an effective treatment method with less side effects. In the application, the traditional Chinese medicine monomer phlorizin can effectively promote the differentiation of Treg cells, and compared with compound traditional Chinese medicine, the use of single component has more advantages in drug efficacy control and efficacy evaluation. In addition, phlorizin is widely sourced, low in cost and non-toxic, and is very suitable for long-term treatment of lupus nephritis.

The present invention relates to antagonistic TNFR2 polypeptides, such as antibodies and antigen-binding fragments thereof, and the use of these polypeptides to inhibit the proliferation of regulatory T cells (T-regs) and / or expand T effector cell populations or function. For example, antibodies of the invention include antagonistic TNFR2 antibodies and antigen-binding fragments thereof, and can be used to suppress the T-reg-mediated deactivation of tumor reactive T-lymphocytes, as well as to treat a wide variety of cancers and infectious diseases.

To provide a cell proliferation system, proliferation method, control method, and culture medium bag capable of proliferating various adherent cells and suspension cells. [Solution] Cells are grown in a bioreactor and activated by an activator (e.g., a soluble activator complex). The nutrient supply and gas exchange functions of an automated closed cell proliferation system make it possible to seed at, for example, a low seeding density. By manipulating the parameters of the cell growth environment, cells are placed in specific locations within the bioreactor for efficient exchange of nutrients and gases. System parameters are adjusted to shear any cell colonies that may form during the proliferation phase. Metabolic concentrations are controlled to improve cell growth and viability. Cell retention within the bioreactor is controlled. In some embodiments, the cells include T cells. In other embodiments, the cells include a T cell subpopulation, for example, regulatory T cells (Tregs).

The present disclosure relates to isolated agonist anti-IL18R antibodies, or fragments thereof, which selectively inhibits tumor-associated regulatory T cells. The disclosure also relates to isolated nucleic acid comprising sequences encoding the antibodies or fragments thereof. The antibodies and fragments thereof can be used for the prevention and / or treatment of cancer.

The application discloses application of a small-molecule drug indisulam in preparation of a drug for treating autoimmune diseases, and further verifies safety of the molecule, long-term continuous use of the drug does not cause weight loss of animals, and weight change has no difference with normal control mice; tissue sections of multiple organs show that the drug has no obvious toxic side effects on each organ. In addition, the drug can promote differentiation of regulatory T cells, but does not affect functions of other immune cells. Therefore, the drug is used for treating autoimmune diseases, and good effect is found.

Therapeutic use and dosing regimen of anti-ICOS antibodies or antigen-binding fragments thereof for modulating the ratio between regulatory T cells and effector T cells, stimulating the immune system of patients, and / or treating tumours or cancers, as monotherapy or combination therapy, e.g., with anti-PD-L1 antibodies or antigen-binding fragments thereof.

Disclosed are a method for producing a cell population in which regulatory T cells have proliferated, including (1) culturing a cell population containing CD4+ T cells derived from pluripotent stem cells in the presence of IL-4 and a TGF-βR agonist, a cell population containing regulatory T cells obtained according to the method, and a medicine containing the cell population containing regulatory T cells.

Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Combinations of anti-ICOS antibodies and other drugs for immunooncology.

The invention relates to the technical field of medicines, and discloses a bifidobacterium longum strain GZBAI 01 and application thereof in degradation of benzoic acid and prevention or treatment of colorectal cancer. The strain is separated from faeces of healthy people, genomics identification is carried out, the metabolic profile of the strain is measured through metabonomics, the strain can convert benzoic acid with carcinogenic risk into protocatechuic acid with antitumor activity through unique metabolic capability, meanwhile, the function of regulatory T cells (Treg) in tumor drainage lymph nodes can be inhibited, differentiation of CD8 + T cells is promoted, and the tumor drainage lymph nodes can be inhibited. Therefore, the colorectal cancer is prevented through double ways of eliminating cancerogen and generating therapeutic agents. A colorectal cancer mouse model and a subcutaneous tumor mouse model verify that the strain can significantly reduce the number and volume of tumors, and shows a benzoic acid conversion effect superior to that of other strains in vivo and in vitro, and a new way is provided for prevention and treatment of colorectal cancer.

Provided here are methods directed to the T cell receptor cloning of heat shock protein 60 (HSP60), the generation of HSP60-specific regulatory T cells (Tregs), and adoptive cell transfer of HSP60-specific Tregs for the treatment of autoimmune and other disorders. Methods of treatment also include administering a therapeutically effective amount of an inhibitor of expression or activity of nucleus accumbens-associated protein- 1 (NAC1) along with the HSP60-specific Tregs.

The invention belongs to the technical field of cancer treatment, and discloses a method for inhibiting castration-resistant prostate cancer proliferation and metastasis by promoting collagen degradation through targeting ADAMTS1. According to the method, ADAMTS1 is determined to be a mechanism key point for linking epigenetic reprogramming with biomechanical microenvironment destruction. The ADAMTS1 is reactivated to degrade a collagen-rich matrix, the FAK / MAPK mechanical transduction signaling pathway is inhibited, and the epithelial-mesenchymal transition (EMT) is reversed. The strategy not only achieves more than 90% of tumor inhibition effect, but also exhausts immunosuppressive macrophages and regulatory T cells to reverse immunosuppression by enhancing toxic CD8 + T cell infiltration. The research determines that epigenetic-ECM coevolution is a symbolic feature of CRPC, and provides a reasonably designed combination therapy for treating castration-resistant prostate cancer.

Provided is a modified regulatory T cell capable of recognizing cells of the liver, capable of treating and / or preventing transplant rejection or immune-mediated damage, and capable of promoting regeneration of cells of the liver.SOLUTION: The present invention provides engineered regulatory T cells (Tregs) comprising a chimeric antigen receptor (CAR), wherein said CAR comprises an antigen recognition domain that specifically binds to the asialoglycoprotein receptor (ASGR). The invention also provides a method of promoting liver tissue repair and / or regeneration in a subject, said method comprising administering to said subject a modified Treg comprising a CAR, or a pharmaceutical composition comprising said modified Treg, wherein said CAR comprises a liver-specific antigen recognition domain.SELECTED DRAWING: None

The invention provides a regulatory T cell with improved phenotype and functional stability and a preparation method and application thereof. The regulatory T cell disclosed by the invention is co-expressed by membrane protein GARP and TGF-beta, and specifically, the TGF-beta comprises a C33S point mutation precursor TGF-beta 1; further, the regulatory T cell co-expresses a cytokine and a sorting marker, specifically, the cytokine comprises IL-10, and the sorting marker comprises a truncated nerve growth factor receptor tNGFR. The regulatory T cell has more stable phenotype and function stability in in-vivo and in-vitro environments, has important enlightenment value for improving the function stability problem of the regulatory T cell in an inflammatory environment, and has wide application prospects in the fields of treatment of autoimmune diseases, intervention of organ transplantation rejection and the like.

The invention relates to the field of biological medicines, relates to a treatment technology for early abortion, and in particular relates to an application of Clostridium prausnitzii (Faecalibacterium prausnitzii) in preparation of a medicine for treating early abortion. An experiment of a Poly (I: C) induced early-stage abortion mouse model proves that the clostridium praeparatum can obviously reduce the embryo loss rate and improve placenta development through oral intragastric administration. The action mechanism is that maternal immune balance is regulated by increasing the proportion of regulatory T cells (Treg) and inhibiting excessive activation of an IL-17 signal channel. As human intestinal symbiotic bacteria, the clostridium praeparatum is high in safety and can be used for intervention of early abortion, especially recurrent abortion, and a new strategy is provided for clinic.

The invention discloses nanoparticles for tumor chemotherapy and immune combined treatment as well as a preparation method and application of the nanoparticles, and belongs to the technical field of biological medicines. The nanoparticles are rHF (at) Cel nanoparticles formed by wrapping tripterine (Cel) with recombinant human heavy chain ferritin (rHF). The preparation method comprises the following steps: obtaining recombinant rHF protein, mixing and assembling Cel and rHF under specific pH and temperature conditions, and purifying to obtain the recombinant rHF protein. The nanoparticles can effectively target tumor cells and release Cel to kill tumors; meanwhile, the rHF carrier can induce polarization of tumor-related macrophages from a tumor-promoting M2 type to an anti-tumor M1 type, reduce the proportion of regulatory T cells (Treg) in a tumor microenvironment and reverse an immunosuppression microenvironment. In-vitro and in-vivo experiments prove that the rHF (at) Cel nanoparticles have a remarkable killing effect on breast cancer cells and can effectively inhibit the growth of transplanted tumors of mice.

The purpose of the present invention is to provide: an antibody that binds to CD25 and has internalizing activity; an antibody-drug conjugate that contains the antibody and has antineoplastic activity; a pharmaceutical product that uses the antibody-drug conjugate and has a therapeutic effect on tumors; and a pharmaceutical product that uses the antibody-drug conjugate and has a therapeutic effect on tumors. A method for treating a tumor using an antibody-drug conjugate or a pharmaceutical product; and the like. The present invention provides a CD25 antibody or an antigen-binding fragment of the antibody, which is characterized by (1) having no IL-2 blocking ability and (2) having an activity of internalizing into a CD25-expressing cell by binding to CD25. The antibody or the antigen-binding fragment of the antibody and a cytotoxic active compound are made into a conjugate, thereby exhibiting the ability to remove regulatory T cells and / or the ability to promote the proliferation of granzyme-positive CD8-positive cells.

The invention discloses an mRNA pollen allergy vaccine and application, and belongs to the technical field of biological medicine. A coding gene segment of the pollen allergen mRNA disclosed by the invention comprises nucleotides as shown in SEQ ID NO.1-4; the pollen allergen mRNA contains at least one of 5 'UTR, 3' UTR and PolyA, the mRNA pollen allergy vaccine is obtained after the pollen allergen mRNA is loaded by the vaccine vector, and the obtained mRNA pollen allergy vaccine can effectively promote generation of antigen-specific regulatory T cells (Treg) and Th1-sex immune response, so that the treatment of pollen allergy is realized. A new thought is provided for the development of pollen allergy treatment and prevention vaccines.

The present invention relates to a composition for treating or preventing neurodevelopmental disorders, particularly autism spectrum disorder, by selectively activating brain-resident regulatory T cells (Tregs). The present composition comprises IL-2 or an IL-2 gene (AAV-GFAP-IL-2) as an active ingredient, and induces Treg proliferation in the brain to alleviate neuroinflammation and improve behavioral defects.

A composition for culturing peripheral blood monocyte-derived regulatory T cells includes at least one antibody selected from the group consisting of anti-CD2, anti-CD3, anti-CD7, anti-CD8, anti-CD28, anti-CD30L, anti-CD40, anti-CD70, anti-CD80, anti-CD83, and anti-CD86; at least one cytokine selected from the group consisting of interleukin-2, interleukin-4, interleukin-7, interleukin-12, interleukin-15, interleukin-34, and TGF-β; and superoxide dismutase. A regulatory T cell culturing method using this composition is also provided. The regulatory T cells according obtained by this method can be utilized for treatment of autoimmune diseases.

Some aspects relate to engineered cells comprising a nucleotide sequence encoding a chimeric antigen receptor (CAR) and at least at first coding exon of a FOXP3 gene, where expression of the CAR and FOXP3 are linked, such that CAR+ cells have a regulatory T cell (Treg) phenotype. Some aspects relate to methods of producing engineered cells in which expression of a CAR and FOXP3 are linked, thereby reducing the incidence of contaminating CAR+ T effector cells. Further aspects relate to methods of screening CARs suitable for expression by a Treg. Some aspects relate to engineered cells expressing an anti-CD19 chimeric antigen receptor (CAR). Some aspects relate to methods of producing engineered cells expressing an anti-CD19 CAR. Some aspects relate to uses of cells expressing anti- CD19 CARs.

The invention provides a probiotic compound for inhibiting anaphylactic reaction. The probiotic compound is prepared from 5 to 15 parts of lactobacillus rhamnosus, 20 to 30 parts of lactobacillus paracasei, 5 to 15 parts of bifidobacterium animalis subsp. Lactis, 1 to 5 parts of bifidobacterium breve, 1 to 5 parts of lactobacillus acidophilus, 1 to 5 parts of plant lactobacillus, 1 to 5 parts of sake lactobacillus brevis, 1 to 5 parts of bifidobacterium longum subsp. Longum and 40 to 55 parts of fructo-oligosaccharide. The probiotic compound is fermented in intestinal tracts to generate metabolite-short-chain fatty acid (consisting of fatty acid with 1-6 carbon atom main chains); the short-chain fatty acid has an anti-inflammatory effect and can enhance an immune protection barrier, such as induction of expansion and de novo differentiation of regulatory T cells; the short-chain fatty acid is a molecule necessary for a B cell differentiation process, and can increase the intake of glucose and promote up-regulation of CXCR < 5 + > and PD-1, so that the growth and development of Tfh cells are realized, and the effect of improving anaphylactic reaction is achieved.

Disclosed is an activator of regulatory T cells, an inhibitor of activity of effector T cells, an inhibitor of activation of B cells, an inhibitor of humoral immunity, or a therapeutic or prophylactic agent for an autoimmune disease, containing a polypeptide including an amino acid sequence equivalent to an HLA-DR binding epitope of an AChR.

Disclosed are compositions and methods for preventing graft versus host disease (GVHD) or allograft rejection in subjects receiving donor cells. Also disclosed are methods enhancing regulatory T (Treg) cells for use in preventing GVHD. Also disclosed are methods of suppressing alloreactive donor cells in a subject receiving transplant donor cells that involves adoptive transfer of the treated Treg cells. Also disclosed are enhanced Treg cells produced by the disclosed methods that have been engineered to express chimeric antigen receptor (CAR) polypeptide cells.

The application discloses a kind of FAP targeted chimeric antigen receptor regulatory T cells, its preparation method and application, belong to biomedical technology field.The FAP targeted chimeric antigen receptor regulatory T cell contains chimeric antigen receptor, the chimeric antigen receptor includes single-chain antibody targeted to FAP, CD8 alpha hinge region, CD8 transmembrane region, CD28 signal region and CD3 zeta signal region, its nucleotide sequence is as shown in SEQ ID NO.1.The FAP targeted chimeric antigen receptor regulatory T cell can effectively accumulate in damaged heart, and control the excessive fibrosis and inflammatory response in MI, which not only highlights the therapeutic potential of CAR Tregs against FAP in promoting heart healing, but also lays the foundation for CAR Treg treatment in clinical environment of severe MI.

The present invention provides a method for selecting a cancer patient for a cancer treatment or for predicting or monitoring the response of a cancer patient to a cancer treatment, comprising: determining the level of effector regulatory T cells in a biological sample from the patient, wherein said level of effector regulatory T cells correlates with the responsiveness of said patient to the cancer treatment.